Mediators of Inflammation · 2012 · 181 citations · 34 references
Life SciencesImmunologyPharmacologyCell SignalingInflammationSignal TransductionAnti-inflammatory PharmacologyInflammation PharmacologyInflammatory SignalingMacrophage BiologyToll-like ReceptorsTumor-associated MacrophagesActivator Protein 1 ActivationAnti-inflammatory ActivityExtracellular Signal-regulated Kinase PathwayMacrophage Inflammatory ResponsesNuclear Factor Kappa B ActivationNuclear Factor Kappa B InhibitionNuclear Factor Kappa B ModulationNuclear Factor Kappa B Signaling
BAY 11-7082 (BAY) is an inhibitor of κB kinase (IKK) that has pharmacological activities that include anticancer, neuroprotective, and anti-inflammatory effects. In this study, BAY-pharmacological target pathways were further characterized to determine how this compound simultaneously suppresses various responses. Primary and cancerous (RAW264.7 cells) macrophages were activated by lipopolysaccharide, a ligand of toll-like receptor 4. As reported previously, BAY strongly suppressed the production of nitric oxide, prostaglandin E(2), and tumor necrosis factor-α and reduced the translocation of p65, major subunit of nuclear factor-κB, and its upstream signaling events such as phosphorylation of IκBα, IKK, and Akt. In addition, BAY also suppressed the translocation and activation of activator protein-1, interferon regulatory factor-3, and signal transducer and activator of transcription-1 by inhibiting the phosphorylation or activation of extracellular signal-related kinase, p38, TANK-binding protein, and Janus kinase-2. These data strongly suggest that BAY is an inhibitor with multiple targets and could serve as a lead compound in developing strong anti-inflammatory drugs with multiple targets in inflammatory responses.
34
A proinflammatory role for IL-18 in rheumatoid arthritis
J. Alastair Gracie, Rosalyn Forsey, Woon Ling Chan et al. · Journal of Clinical Investigation · 1999 · 643 citations · Full text
Medicine, Immunology, Pathobiology +17